(Q33345788)

26 July 2017

title

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

1 reference

Tarek Mekhail

1

1 reference

26 July 2017

Thomas E Hutson

2

1 reference

26 July 2017

Paul Elson

3

1 reference

26 July 2017

G Thomas Budd

4

1 reference

26 July 2017

Gordon Srkalovic

5

1 reference

26 July 2017

Thomas Olencki

6

1 reference

26 July 2017

David Peereboom

7

1 reference

26 July 2017

Robert Pelley

8

1 reference

26 July 2017

Ronald M Bukowski

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

97

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

170-178

1 reference

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel delivers new management opportunities for gastrointestinal carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel: an active drug for squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel and interstitial pulmonary injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

A dose escalation study of weekly docetaxel in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10991

7 January 2021

Identifiers

DOI

10.1002/CNCR.10991

1 reference

26 July 2017

1 reference